New rules on medical force majeure and the medical certificate
For the version in FRENCH, click here.
For the version in DUTCH, click here.
A new Act, which includes various provisions on incapacity for work, was published in the Belgian State Gazette on 18 November 2022.
This Act, which will enter into force on 28 November 2022, contains the following three important new measures regarding sick employees:
(i) The already-announced new and enhanced procedure for determining medical force majeure, which will shortly be completely separated from the re-integration track for the reinstatement of sick employees in the company; and
(ii) The exemption from submitting a medical certificate, three times a year, for the first day of illness for workers in companies with at least 50 workers; and
(iii) The exemption from the employer’s payment of the guaranteed salary when the employee becomes incapacitated again during the first 20 weeks of a partial resumption of work with the consent of the health insurance fund’s advisory doctor.
We briefly explain these new measures below.
The new track to determine medical force majeure
The ‘old’ re-integration track, which was introduced to guide long-term ill employees to other or adapted work within the company, was in the past often used as a facilitator for a ‘medical force majeure termination’.
This will no longer be possible. Indeed, from 28 November 2022, medical force majeure will have to be established through a separate ‘medical force majeure’ track, which has been completely separated from the re-integration track. The re-integration track, in turn, has received a face-lift, which we recently informed you about in our October 2022 newsflash.
When can this medical force majeure track be initiated?
The procedure for medical force majeure may only be initiated:
- After at least 9 months of incapacity for work; and
- To the extent that no re-integration track is ongoing.
In the case of a work resumption, the 9-month period will be interrupted and the ‘counter’ will be reset to zero, unless this work resumption lasts less than 14 days.
How does this procedure work?
When will termination for medical force majeure be possible?
Termination for medical force majeure will only be possible if the occupational doctor has decided that the employee is indeed definitively incapable of performing the agreed work, the appeal procedure has been exhausted, and:
1. The employee has not asked to examine the possible options for adapted or different work; or
2. The employee did ask to examine the options for adapted or other work, but the employer made a reasoned report that any adapted or other work is not available within the company; or
3. The employee did ask to examine the options for adapted or other work, but refused the other or adapted work offered by the employer.
If the occupational doctor does not establish that it is definitively impossible for the employee to perform the agreed work, then the procedure for medical force majeure is terminated. It can only be restarted after a new 9-month period of incapacity for work.
Exemption from submitting a medical certificate for the first day of illness
If so provided for in the work rules or in a collective bargaining agreement, the employee must submit a medical certificate in the case of any work incapacity.
Following the new law, the employee will now be exempted from this obligation to submit a medical certificate three times a year for the first day of work incapacity. This applies both to absences of one day due to work incapacity and to the first day of a longer absence.
However, the employee must inform the employer at which address he/she will reside on this first day of incapacity if this address differs from his/her usual place of residence.
Companies that employ less than 50 employees can deviate from this exemption and thus also require a medical certificate for the first day of work incapacity if they explicitly include this deviation in their work rules or in a collective bargaining agreement.
Guaranteed salary in the case of partial work resumption
In the case of partial work resumption with the consent of the health insurance fund’s advisory doctor, the employer will not be obliged to pay guaranteed salary if the employee becomes incapacitated for work again during the first 20 weeks of his/her resumption of work.
However, the employee will again be entitled to guaranteed salary if he/she becomes incapacitated for work again after this 20-week period.
Written by
Recommended articles
EU General Court bars patient association from challenging medicine authorisation refusal
In Case T‑278/25, the EU General Court recently dismissed as inadmissible a challenge brought by a patient advocacy association against the European Commission’s refusal to renew the conditional marketing authorisation for a treatment against Duchenne muscular dystrophy (DMD). The case is significant because it adds to the case law on contesting Commission decisions relating to the marketing of medicinal products. In this blog post, we look at how the Court came to the conclusion that the association lacked standing to litigate and use this as a basis for an informal categorisation of the existing case law.
Read on
Despite EU harmonisation, Member States may impose authorisation requirements on pharmacy-prepared medicines, rules EU Court of Justice
Under EU pharmaceutical law, certain medicines fall outside the scope of Directive 2001/83/EC (i.e. the Community code on medicinal products for human use). This includes “magistral formulae” (prepared in a pharmacy for an individual patient on prescription) and “officinal formulae” (prepared in a pharmacy in accordance with a pharmacopoeia and supplied directly to that pharmacy’s […]
Read on
EU General Court: technical vaccine data does not have to be disclosed on request
The EU General Court delivered a significant judgment concerning access to documents held by the European Medicines Agency (EMA), this time relating to a conditionally authorised COVID-19 vaccine. This case (T-623/22) serves as an addition to the elaborate case law on the balance between transparency in health matters and the protection of companies' commercial interests. On this (rare) occasion, the commercial interests of the conditional marketing authorisation (‘MA’) holder prevailed, although an appeal is currently pending (C-38/26 P).
Read on